Cancer cells benefit from altered control of the HIF1 signaling pathway (Schito and Semenza, 2016), HIF1 is often associated with acute or chronic inflammatory disorders (Imtiyaz and Simon, 2010), and HIF1 plays a role in the pathology of insulin resistance as well as non-alcoholic fatty liver disease (Lefere et al., 2016). This evidence concerns the gene HIF1A and cancer.